MedTrace Logo

Real-world Study for Patients With Advanced Hepatobiliary Tumors

NCT03892577 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2023-03-29

No results posted yet for this study

Summary

The investigators design a large sample size study in the real-world to explore whether targeted therapy and immunotherapy can improve the survival, quality of life and drug safety of patients with advanced hepatobiliary tumors, and analyze the correlation between genetic variation and the effectiveness of therapy.

Conditions

  • Objective Response Rate
  • Progression-free Survival
  • Overall Survival
  • Disease Control Rate
  • Duration of Response
  • Five-year Survival Rate
  • Quality of Life

Interventions

DRUG

Precision oncology including targeted therapy and immunotherapy

Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.

Sponsors & Collaborators

  • OrigiMed

    collaborator INDUSTRY

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Haitao Zhao · Chinese Academy of Medical Sciences & Peking Union Medical College Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2023-10-01
Completion
2025-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03892577 on ClinicalTrials.gov